Last updated on April 2018

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acute Myocardial Infarction | Acute Coronary Syndrome | Percutaneous Coronary Intervention | Platelet Aggregation Inhibitors | Coronary Artery Disease | Coronary heart disease
  • Age: - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients received percutaneous coronary intervention with cobalt-chromium everolimus-eluting stent under the setting of acute coronary syndrome
  • Patients who are capable of oral dual antiplatelet therapy consisting of aspirin and P2Y12 receptor antagonist

Exclusion Criteria:

  • Patients requiring oral anticoagulants
  • Patients with medical history of intracranial hemorrhage
  • Patients who have experienced serious complications (myocardial infarction, stroke, and major bleeding) during hospital stay after percutaneous coronary intervention
  • Patients with drug eluting stents other than Cobalt chromium everolimus eluting stents implanted at the time of enrollment
  • Patients confirmed to have no tolerability to clopidogrel before enrollment
  • Patients requiring continuous administration of antiplatelet drugs other than aspirin and P2Y12 receptor antagonists at the time of enrollment

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.